Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis

Amber C. Streifel; Luke C. Strnad; Monica K. Sikka; Cara D. Varley; Jina Makadia; Ellie Sukerman; Alyse H. Douglass; Heather Mayer; Kathleen Young; James S. LewisII

doi:10.1093/ofid/ofae070

Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis

Amber C. Streifel
, Luke C. Strnad
, Monica K. Sikka
, Cara D. Varley
, Jina Makadia
, Ellie Sukerman
, Alyse H. Douglass
, Heather Mayer
, Kathleen Young
, James S. LewisII

Infectious Diseases

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.

Original language	English (US)
Article number	ofae070
Journal	Open Forum Infectious Diseases
Volume	11
Issue number	3
DOIs	https://doi.org/10.1093/ofid/ofae070
State	Published - Mar 1 2024

Keywords

OPAT
long-acting glycopeptides
vertebral osteomyelitis

ASJC Scopus subject areas

Oncology
Infectious Diseases

Access to Document

10.1093/ofid/ofae070

Cite this

@article{bb934d03460b4770875b47a1bde9862d,

title = "Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis",

abstract = "Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3\%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6\%) and infection recurrence in 3 (8.8\%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.",

keywords = "OPAT, long-acting glycopeptides, vertebral osteomyelitis",

author = "Streifel, \{Amber C.\} and Strnad, \{Luke C.\} and Sikka, \{Monica K.\} and Varley, \{Cara D.\} and Jina Makadia and Ellie Sukerman and Douglass, \{Alyse H.\} and Heather Mayer and Kathleen Young and LewisII, \{James S.\}",

year = "2024",

month = mar,

day = "1",

doi = "10.1093/ofid/ofae070",

language = "English (US)",

volume = "11",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis

AU - Streifel, Amber C.

AU - Strnad, Luke C.

AU - Sikka, Monica K.

AU - Varley, Cara D.

AU - Makadia, Jina

AU - Sukerman, Ellie

AU - Douglass, Alyse H.

AU - Mayer, Heather

AU - Young, Kathleen

AU - LewisII, James S.

PY - 2024/3/1

Y1 - 2024/3/1

N2 - Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.

AB - Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.

KW - OPAT

KW - long-acting glycopeptides

KW - vertebral osteomyelitis

UR - https://www.scopus.com/pages/publications/85187158690

UR - https://www.scopus.com/pages/publications/85187158690#tab=citedBy

U2 - 10.1093/ofid/ofae070

DO - 10.1093/ofid/ofae070

M3 - Article

AN - SCOPUS:85187158690

SN - 2328-8957

VL - 11

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 3

M1 - ofae070

ER -

Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this